Reports
Sale
Global Cancer Immunotherapy Market Size, Share, Growth, Analysis, Forecast; By Therapy Type: Monoclonal Antibodies, Cancer Vaccines, Immunomodulators, Immune Check Point Inhibitors, Others; By Application: Prostate Cancer, Breast Cancer, Others; By Distribution Channels; By End Use; Regional Analysis; Supplier Landscape; 2024-2032
Global Cancer Immunotherapy Market Outlook
The global cancer immunotherapy market size attained a value of USD 106.6 billion in 2023. The market is likely to grow at a CAGR of 11.60% during the forecast period of 2024-2032 to attain a value of USD 284.7 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Increasing Demand for Monoclonal Antibodies to Catalyse the Growth of the Global Cancer Immunotherapy Industry
Based on therapy type, the monoclonal antibodies segment is expected to hold a significant share in the global cancer immunotherapy industry during the forecast period. This growth can be attributed to the heightened implementation of monoclonal antibodies therapy in cancer treatment globally. Monoclonal antibodies are immune system proteins created in the lab. Antibodies help the immune system to identify disease-causing bacteria and viruses and target them. For example, rituximab binds to a protein called CD20 on B cells, a type of white blood cells, and some types of cancer cells, causing the immune system to attack them. These factors are estimated to drive the market growth in the forecast period.
North America to Possess a Substantial Market Share in the Global Cancer Immunotherapy Industry
North America is predicted to hold a considerable market share in the global cancer immunotherapy industry. This surge can be attributed to the increased adoption of cancer immunotherapy in the region. In addition, the growing prevalence of cancer in the region has enhanced the demand for immunotherapies. According to the statistics given by National Cancer Institute, as of January 2019, there were an estimated 16.9 million cancer survivors reported in the United States. Further, the number of cancer survivors is projected to increase to 22.2 million by 2030. These factors are estimated to drive the market growth in the region.
Cancer Immunotherapy: Market Segmentation
Cancer refers to diseases that can originate in any organ or tissue of the body where abnormal cells grow unnaturally and go beyond their usual boundaries to invade nearby body parts, also known as metastasizing. According to WHO, cancer is the second leading cause of death globally. Among men, lung, prostate, colorectal, stomach, and liver cancer are the most common types of cancer. In contrast, breast, colorectal, lung, cervical and thyroid cancer are the most common cancer types among women. In this regard, immunotherapy is a treatment for cancer that helps and supports a patient's immune system to fight cancer by providing a boost to the immune system's natural defences to locate and attack cancer cells in the body.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
By therapy type, the market is distributed into:
- Monoclonal Antibodies
- Cancer Vaccines
- Immunomodulators
- Immune Check Point Inhibitors
- Others
On the basis of application, the industry can be categorised into:
- Prostate Cancer
- Breast Cancer
- Skin Cancer
- Lung Cancer
- Others
Based on end use, the market can be segmented into:
- Hospitals and Clinics
- Cancer Research Centres
- Others
The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Heightened Prevalence of Cancer to Augment the Growth of the Global Cancer Immunotherapy Industry
According to the WHO statistics, cancer is the second leading cause of death globally, with around 9.6 million casualties reported in 2018. In 2020, the number of cancer cases reported was 19.3 million, and this number is estimated to rise to 30.2 million by 2040. Among these, the most commonly found cancer is breast cancer. In 2020, an estimated 2.3 million women were diagnosed with breast cancer and 685 000 deaths globally. Observing the growing prevalence of cancer worldwide, governments and international organisations are increasingly devising strategies and conceptualising initiatives to raise funds and awareness about cancer and its potential prevention. For instance, the WHO initiative, Global Breast Cancer Initiative (GBCI), aims to reduce the mortality rate by 2.5% every year, which would help to prevent 40% of cancer deaths by 2040. Their main objectives include health promotion for early detection, timely diagnosis, and comprehensive breast cancer management. Such developments are expected to drive market growth in the forecast period.
Key Industry Players in the Global Cancer Immunotherapy Market
The report gives a detailed analysis of the following key players in the global cancer immunotherapy market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
- Amgen Inc.
- Astellas Pharma Inc.
- AstraZeneca plc
- Bayer AG
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche AG
- Others
The comprehensive EMR report provides an in-depth assessment of the industry based on the Porter's five forces model and SWOT analysis.
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Therapy Type |
|
| Breakup by Application |
|
| Breakup by Distribution Channels |
|
| Breakup by End Use |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Cancer Immunotherapy Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Cancer Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Cancer Epidemiology (2016-2031)
5.3 Europe Cancer Epidemiology (2016-2031)
5.4 Asia-Pacific Cancer Epidemiology (2016-2031)
5.5 Latin America Cancer Epidemiology (2016-2031)
5.6 Middle East & Africa Cancer Epidemiology (2016-2031)
6 Global Cancer Immunotherapy Market Overview
6.1 Global Cancer Immunotherapy Market Historical Value (2017-2023)
6.2 Global Cancer Immunotherapy Market Forecast Value (2024-2032)
7 Global Cancer Immunotherapy Market Landscape
7.1 Global Cancer Immunotherapy Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Global Cancer Immunotherapy Product Landscape
7.2.1 Analysis by Therapy Type
7.2.2 Analysis by End User
7.2.3 Analysis by Applications
8 Cancer Immunotherapy Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Cancer Immunotherapy Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Cancer Immunotherapy Market Segmentation
11.1 Global Cancer Immunotherapy Market by Therapy Type
11.1.1 Market Overview
11.1.2 Monoclonal Antibodies
11.1.3 Cancer Vaccines
11.1.4 Immunomodulators
11.1.5 Immune Check Point Inhibitors
11.1.6 Others
11.2 Global Cancer Immunotherapy Market by Application
11.2.1 Market Overview
11.2.2 Prostate Cancer
11.2.3 Breast Cancer
11.2.4 Skin Cancer
11.2.5 Lung Cancer
11.2.6 Melanoma
11.2.7 Others
11.3 Global Cancer Immunotherapy Market by Distribution Channels
11.3.1 Market Overview
11.3.2 Hospitals Pharmacy
11.3.3 Retail Pharmacy
11.3.4 Online Pharmacy
11.3.5 Others
11.4 Global Cancer Immunotherapy Market by End Use
11.4.1 Market Overview
11.4.2 Hospitals & Clinics
11.4.3 Cancer Research Centers
11.5 Global Cancer Immunotherapy Market by Region
11.5.1 Market Overview
11.5.2 North America
11.5.3 Europe
11.5.4 Asia Pacific
11.5.5 Latin America
11.5.6 Middle East and Africa
12 North America Cancer Immunotherapy Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Cancer Immunotherapy Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Cancer Immunotherapy Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Cancer Immunotherapy Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Cancer Immunotherapy Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Regulatory Framework
22.1 Regulatory Overview
22.1.1 US FDA
22.1.2 EU EMA
22.1.3 INDIA CDSCO
22.1.4 JAPAN PMDA
22.1.5 Others
23 Supplier Landscape
23.1 AstraZeneca
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 F. Hoffmann-La Roche Ltd
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Amgen Inc.
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Astellas Pharma Inc.
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Bayer AG
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Bristol-Myers Squibb Company
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Novartis AG
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Genentech, Inc (Roche)
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Lilly
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Johnson & Johnson Services, Inc
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Immunocore, Ltd
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
23.12 Merck
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisitions
23.12.5 Certifications
24 Global Cancer Immunotherapy Market- Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The cancer immunotherapy Market was valued at USD 106.6 billion in 2023.
The market is expected to grow at a CAGR of 11.60% from 2024 to 2032 to reach a value of USD 284.7 billion by 2032.
The major drivers of the industry include rapidly growing geriatric global population, rising numbers of casualties of different cancer varieties, increased adoption of cancer immunotherapy and heightened implementation of monoclonal antibodies therapy in cancer treatment.
The key market trends guiding the industry's growth include the growing prevalence of cancer worldwide and government initiatives to raise funds and awareness about cancer and its potential prevention.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The market is divided based on therapy type into monoclonal antibodies, cancer vaccines, immunomodulators, and immune check point inhibitors, among others.
The significant applications include into prostate cancer, breast cancer, skin cancer, and lung cancer, among others.
The significant segments based on end-use include hospitals and clinics and cancer research centres, among others.
The major players in the industry are Amgen Inc., Astellas Pharma Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, and F. Hoffmann-La Roche AG., among others.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$ 3499
$1999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5999
$2999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 7999
$3999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9999
$5999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER